HIV Vaccine Candidate Study in Nigeria
Author Information
Author(s): Agwale Simon M., Forbi Joseph C., Notka Frank, Wrin Terri, Wild Jens, Wagner Ralf, Wolf Hans
Primary Institution: Innovative Biotech, Nigeria
Hypothesis
The study aims to determine the breadth and strength of neutralizing antibodies against primary HIV-1 isolates in a cohort of HIV-1 infected Nigerians.
Conclusion
The study identified three broadly cross-neutralizing sera and developed candidate vaccine constructs that induced strong immune responses in mice.
Supporting Evidence
- Three patient plasma samples showed extensive cross-neutralization of other primary isolates.
- Envelope gp140 sequences from the identified sera were codon-optimized and evaluated in mice.
- The study demonstrated that a CRF02_AG and G based vaccine can stimulate humoral and cell mediated responses.
Takeaway
Scientists are trying to create a vaccine for HIV by studying blood samples from people in Nigeria to see how well their bodies can fight the virus.
Methodology
Blood samples were collected from HIV-1 infected individuals, and neutralizing antibodies were assessed using the PhenoSense HIV neutralizing antibody assay.
Potential Biases
Potential biases may arise from the selection of participants and the specific geographic focus of the study.
Limitations
The study's findings may not be generalizable beyond the specific cohort of Nigerian individuals tested.
Participant Demographics
Participants were HIV-1 infected individuals from Nigeria.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website